Try our corporate solution for free!
+1 (212) 419-5770

Revenue of Ablynx 2013-2017

This statistic illustrates the revenue of Ablynx from 2013 to 2017. Ablynx is a Belgian biopharmaceutical company engaged in the discovery and the development of nanobodies. In 2018, the French pharmaceutical company Sanofi acquired Ablynx for 3.9 billion euros. As of 2017, the revenue of Ablynx amounted to roughly 56 million euros, which is less than in the previous year, when Ablynx generated a revenue of approximately 85 million euros.

Revenue of Ablynx from 2013 to 2017

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until October 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

February 2018


Worldwide, Belgium

Survey time period

2013 to 2017

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.